Open Access<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>
Author(s) -
Leilei Ai,
Jian Chen,
Yan Hao,
Qiaojun He,
Peihua Luo,
Zhifei Xu,
Xiaochun Yang
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s267433
Subject(s) - adverse effect , clinical trial , medicine , monoclonal antibody , pd l1 , immune system , cancer , oncology , immunotherapy , antibody , pharmacology , immunology
PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. However, the serious immune-related adverse reactions limited the clinical application of PD-1/PD-L1 monoclonal antibodies, despite the promising curative effects. Therefore, it is urgent to develop novel inhibitors, such as small molecules, peptides or macrocycles, targeting the PD-1/PD-L1 axis to meet the increasing clinical demands. Our review discussed the mechanism of action of PD-1/PD-L1 inhibitors and presented clinical trials of currently approved PD-1/PD-L1 targeted drugs and the incidence of related adverse reactions, helping clinicians pay more attention to them, better formulate their intervention and resolution strategies. At last, some new inhibitors whose patent have been published are listed, which provide development ideas and judgment basis for the efficacy and safety of novel PD-1/PD-L1 inhibitors.